Selexis names Yemi Onakunle as vp of strategic and market development

Former Diosynth and Lonza executive joins Swiss life science company

Geneva, Switzerland-based Selexis has hired Yemi Onakunle as vice president of strategic and market development. He will be responsible for expanding Selexis' presence in the drug discovery, next generation biologics and difficult-to-express protein markets.

Onakunle has more than 15 years' experience in drug manufacturing and cell line development. Prior to joining Selexis, he was director of commercial development at Diosynth RTP and associate director of business development at Lonza Custom Manufacturing.

More recently, Onakunle was head of sales and marketing at Bachem Americas, a contract manufacturing organisation focusing on peptides and complex organic molecules.

Onakunle is a member of the board of directors of VLP Biotech, a vaccine development company based in San Diego, CA and has been a business advisor to several biopharmaceutical and drug delivery companies.

You may also like

Research & Development

Faron links up with Selexis to progress development of cancer antibody

Under the agreement, Faron will have access to the Selexis SUREtechnology platform and SURE CHO-M cell line
Manufacturing

JHL Biotech and Selexis form biologic drug development alliance

Will provide seamless services from cell line development to cGMP manufacturing
Research & Development

Dual inhibition of motor proteins KIF18A and CENP-E shown to selectively kill cancer cells

Researchers from Osaka University and MIT have discovered that blocking two cooperative motor proteins involved in chromosome alignment can trigger cancer cell death, revealing a promising new target for anticancer therapies
Research & Development

EVerZom and GENFIT partner for research collaboration for liver failure candidate EViv

The agreement will support EVerZom’s dynamic development strategy and follows the recent announcement of a €10m financing round aimed at accelerating its clinical and partnering roadmap
Research & Development

Samsung Epis launches subsidiary Epis NexLab for next-gen biotech platform development

Epis NexLab will focus on transforming highly scalable peptide-related technologies into development platforms for the discovery of new drug candidates, including license-out or joint development with global pharmaceutical companies
Sustainability

Guardtech supporting malaria fight in East Africa with portable 11-bay lab

Suffolk-based experts provide Cleancube Multi 11 for Oxitec’s Friendly mosquito programme in Djibouti
Ingredients

Optimising sample traceability with laser marking technology

Speed and precision in high-throughput tube identification
Subscribe now